Bioxyne Targets A$1M+ Revenue with New Central American Cannabis Agreement
Bioxyne Limited has secured a pioneering manufacturing and supply agreement to enter the emerging medicinal cannabis markets of Costa Rica and Panama, positioning itself as a first mover with promising revenue potential.
- First manufacturing and supply agreement in Central America
- Focus on pharmaceutical-grade THC pastilles for Costa Rica and Panama
- Potential annual revenue exceeding A$1 million post regulatory approvals
- Supports Bioxyne’s FY26 revenue target of A$65–75 million and EBITDA of A$11.5–13.5 million
- Partnership with Canadian-affiliated Remidose LATAM SRL
Bioxyne’s Strategic Entry into Central America
Australian pharmaceutical company Bioxyne Limited (ASX – BXN) has taken a significant step into the emerging medicinal cannabis markets of Central America by signing a manufacturing and supply agreement with Remidose LATAM SRL, a Costa Rican entity linked to Canadian medicinal cannabis specialist Remidose Aerosols Inc. This deal marks Bioxyne’s first foray into Costa Rica and Panama, two markets poised for growth but still in early development stages.
Under the agreement, Bioxyne’s wholly owned subsidiary, Breathe Life Sciences (BLS), will manufacture pharmaceutical-grade THC pastilles, non-flower cannabis dosage forms expected to dominate these markets. The partnership leverages BLS’s reputation as a GMP-certified manufacturer known for high-quality, precisely dosed medicinal cannabis products.
Market Potential and Revenue Outlook
The agreement includes minimum order commitments of 40,000 units annually across Costa Rica and Panama, with indicative pricing suggesting potential revenue exceeding A$1 million once regulatory approvals from the Therapeutic Goods Administration (TGA) and local market registrations are secured. This first-mover position in relatively low-competition markets aligns with Bioxyne’s broader FY26 growth ambitions, which target revenues between A$65 million and A$75 million, alongside an EBITDA range of A$11.5 million to A$13.5 million.
Remidose LATAM’s President and CEO Ludwig Muller highlighted the strategic importance of medicinal pastilles in Latin America, noting the increasing adoption of GMP standards across countries like Costa Rica. The partnership aims to deliver high-quality, accurately dosed cannabis medicines to underserved patient populations, reinforcing Bioxyne’s role in expanding access to innovative therapeutics.
Broader Implications and Next Steps
Bioxyne’s expansion into Central America complements its existing multinational footprint, which includes operations in Australia, Japan, the UK, and Europe. BLS’s capabilities extend beyond cannabis to other controlled substances such as psilocybin and MDMA, positioning the company at the forefront of alternative therapeutics manufacturing.
While the agreement is subject to regulatory approvals, the deal’s rolling 12-month term with automatic renewal offers Bioxyne a stable platform to build market presence. Investors will be watching closely as the company navigates export licensing and local registrations, milestones that will validate the commercial potential of this partnership.
Bottom Line?
Bioxyne’s Central American deal sets the stage for global growth but hinges on timely regulatory approvals to unlock its full revenue potential.
Questions in the middle?
- How quickly will Bioxyne secure TGA export and local market approvals?
- What is the competitive landscape for medicinal cannabis in Costa Rica and Panama?
- Could this partnership pave the way for Bioxyne’s expansion into broader Latin American markets?
